Angelalign (6699 HK, HK$84.15, HK$14.4bn) — A Promising Global Expansion

Angelalign is evolving from China’s clear-aligner leader into a global orthodontic platform. Overseas expansion has grown rapidly over the past few years, but heavy upfront investment continued to weigh on earnings and obscured the underlying resilience of the core business in China. As clinical outcomes gain wider validation, Angelalign is winning greater acceptance among overseas orthodontists, with repeat usage and doctor referrals increasingly supporting case growth. Overseas operating profit turned positive for the first time in 1H26 as operating leverage kicked in. We believe the company is moving from an investment-led growth phase toward scale-driven profit expansion, with overseas markets set to become an increasingly important earnings engine.

Becoming A Valid Challenger: Since 2022, Angelalign has been investing its cash flow generated from the China business to expand overseas through local operations and selective M&A across Europe, Asia Pacific, Brazil and North America. Rather than directly challenging Invisalign as doctors’ primary brand, Angelalign has initially entered as a second supplier, supported by local sales, doctor education, clinical support and service capabilities.

Given more clinical support, its overseas operation begins to receive repeat usage, higher utilization and doctor referrals. Leveraging on Aditek’s local manufacturing in Brazil, medical-design capacity in Southeast Asia and the Wisconsin plant in the US, it has established a speedy supply chain and local service capabilities.

The overseas business is now delivering robust growth in volume, pricing and profitability. Market share remains in the single digits, but stronger brand recognition, lower introductory discounts and a higher mix of complex cases should support modest ASP improvement. Meanwhile, economies of scale are beginning to take effect, allowing operating leverage to emerge.

We expect overseas case volume to grow at a mid-teens rate, alongside MSD ASP growth, supporting revenue growth of around 20% or above. GPM should remain at around 60%, while further operating leverage should continue to improve segment profitability.

China Enters a New Phase of Growth: China remains Angelalign’s core earnings base and continues to fund overseas expansion. Between 2022 and 2024, centralized procurement, competition and a shift towards lower-priced products pressured ASP and hence margins. However, case volume continued to increase, highlighting resilient underlying demand despite a changing growth mix.

This transition is becoming more evident, with growth increasingly driven by lower-tier cities and pediatric and early-intervention orthodontics, while industry consolidation continues to favor leading players. Angelalign, Smartee and Invisalign now combined for nearly 90% of the market, with Angelalign retaining its leading position at around 35% of the market.

ASP may remain under pressure by centralized procurement and a higher mix of lower-priced products.  However, stronger case growth and continued efficiency gains from automation, unit-cost reductions and better cost absorption should support stability to modestly improving margins. Domestic growth should increasingly rely on case expansion and scale efficiencies rather than pricing.

Our View: Clear aligners are not a market where price alone can alter market share. Competitive barriers are built around clinical case accumulation, treatment-planning capabilities, doctor loyalty and long-term service infrastructure. Orthodontists are cautious about switching brands as they are ultimately responsible for treatment outcomes. A larger case base also strengthens treatment planning and complex-case capabilities, while better outcomes reinforce doctor confidence, repeat usage and referrals.

The barriers are even higher overseas, where successful expansion requires local sales, doctor education, clinical support, medical design and reliable fulfillment. Angelalign has vowed to build these capabilities while investing in local manufacturing to shorten delivery times and improve service responsiveness.

We are positive on the company given its ability to maintain a profitable China franchise while sustaining overseas growth.  As Angelalign is transitioning from heavy investment toward harvesting, it should warrant a re-rating as overseas earnings continue to grow. The counter is trading at 49x FY26E and 31x FY27E P/E. (Research Department)